Moderna, Inc.’s Stock Price Soars to $27.24, Marking a Robust 4.73% Increase

Moderna, Inc. (MRNA)

27.24 USD +1.23 (+4.73%) Volume: 11.1M

Moderna, Inc.’s stock price sees a positive surge of +4.73% this trading session, currently standing at 27.24 USD, despite a significant YTD decline of -34.49%, with a strong trading volume of 11.1M.

Latest developments on Moderna, Inc.

Moderna’s stock price movement today is influenced by a series of key events leading up to it. The company recently announced data on flu and pandemic flu candidates at IDWeek 2025, highlighting its focus on vaccine development beyond COVID-19. Additionally, a study suggesting that Moderna’s COVID-19 shot enhances the efficacy of cancer treatment has boosted investor confidence. Despite receiving a Hold Rating from Needham & Company LLC, Moderna’s updated COVID-19 vaccine remains essential against emerging variants. The company’s mRNA vaccines have also shown promise in boosting the effects of certain cancer treatments, shaping its pipeline diversification narrative. With multiple vaccine data presented at IDWeek 2025 and a surge in stock price as the White House announces a new immunization effort, Moderna remains a key player in the post-COVID race.

Moderna, Inc. on Smartkarma

Analysts at Baptista Research have provided bullish coverage on Moderna, Inc., highlighting the company’s expansion beyond respiratory vaccines as a key to long-term success. The recent earnings report for the second quarter of 2025 showed revenues of $2.1 billion and a loss of $0.8 billion, in line with company expectations. Moderna also managed to reduce its cost of sales and SG&A by 35% compared to the previous year, demonstrating a commitment to financial discipline. For more insights, you can visit Baptista Research‘s profile on Smartkarma.

Another report from Baptista Research focuses on Moderna’s oncology innovations and pipeline expansion post-Covid vaccine era. Despite a net loss of $1 billion in first-quarter 2025, the company remains optimistic about its future prospects. The analysts believe that the strategic developments in the oncology sector could be the much-needed breakthrough for Moderna. To access the full report, you can visit the insight link on Smartkarma.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Moderna has a positive long-term outlook. With a high Value score of 5, the company is deemed to be undervalued, which could indicate potential for growth in the future. Although Moderna has a low Dividend score of 1, the company’s focus on developing mRNA therapeutics and vaccines for various diseases positions it well for future growth opportunities. Additionally, with scores of 3 for both Resilience and Momentum, Moderna shows stability and potential for continued success in the biotechnology industry.

Moderna, Inc. is a biotechnology company that specializes in developing messenger RNA therapeutics and vaccines. The company’s focus on infectious, immuno-oncology, and cardiovascular diseases highlights its commitment to addressing a wide range of health concerns. With a strong Value score of 5, Moderna is seen as undervalued, indicating potential for growth. While the company’s Dividend score is low at 1, its Growth score of 2 suggests that Moderna is poised for expansion in the coming years. With respectable scores for Resilience and Momentum, Moderna appears to be well-positioned for long-term success in the biotechnology sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma